Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Clinical correlation of the IHC results for the 72 Stage I-IV invasively malignant neoplasms revealed no statistically significant association of the intensity of NEU IHC staining with either relapse-free or overall survival.
|
1347282 |
1992 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
One hundred seventy-nine primary human gastric tumors not associated with early cancer or noncurative resection were examined immunohistochemically for the expression of c-erbB-2 protein.
|
1348293 |
1992 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The HER-2/neu gene was found both in normal ovaries and malignant tumors, without any apparent difference among the various histological types.
|
1349908 |
1992 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The proto-oncogene designated erbB2 or HER2 encodes a 185-kilodalton transmembrane tyrosine kinase (p185erbB2), whose overexpression has been correlated with a poor prognosis in several human malignancies.
|
1350381 |
1992 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Fifty-five (26%) patients had cancer and a positive HER-2 oncoprotein stain reaction.
|
1351537 |
1992 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in transmembrane domain of c-erbB-2 gene in human malignant tumours of the central nervous system.
|
1355276 |
1992 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In marked contrast, c-erbB-2 proto-oncogene expression was found only in adenocarcinoma cells, and thus can be used as a marker for malignancy in diagnostic respiratory cytopathology.
|
1355655 |
1992 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The HER-2/neu gene was found both in normal ovaries and malignant tumors, without any apparent difference among the various histological types.
|
1634822 |
1992 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This expression was regarded as baseline activity of the neu gene for the respective tissues and was used as standard for the evaluation of benign and malignant tumors.
|
1672262 |
1991 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This assay, and the quantitation of shed antigen levels, may have diagnostic or monitoring utility in cancers, such as breast and ovarian, in which the c-erbB-2 protein is overexpressed.
|
1673637 |
1991 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
|
1679763 |
1991 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The proto-oncogenes c-erbB-2 and epidermal growth factor (EGF) receptor which encode 2 closely homologous transmembrane glycoproteins have been found amplified and/or overexpressed in a range of epithelial malignancies.
|
1685773 |
1991 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To date, no urothelial malignancies appear to have been evaluated for HER-2/neu DNA amplification, mRNA expression and protein overproduction.
|
1942310 |
1991 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Among the neoplasms assayed p185 HER2 was expressed in 46% of primary breast cancers, in 28% of ovarian tumors and in 30% of colon rectum malignancies.
|
1968437 |
1990 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Evidence that the c-erbB-2 proto-oncogene is important in prognosis and oncogenesis in a number of human malignancies is increasing.
|
1979342 |
1990 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Amplification and/or overexpression of c-erbB-2 in breast adenocarcinomas occurs frequently and its occurrence implies a more advanced malignancy.
|
1981830 |
1990 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases.
|
2156604 |
1990 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
One hundred and four common epithelial malignancies of the ovary were stained for c-erbB-2 using an affinity-purified polyclonal antibody 21N.
|
2266460 |
1990 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest possible involvement of the c-erbB-2 gene in human cancer.
|
2430175 |
1986 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Comparison of erbB-2 overexpression with clinical disease parameters revealed a correlation of this alteration with inflammatory mammary carcinoma (P = 0.042) implying an association of elevated erbB-2 protein levels with enhanced malignancy of the tumor cell in vivo.
|
2564657 |
1989 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This localization may facilitate the search for human malignancies with chromosome changes involving the erbB-2 gene.
|
2565881 |
1989 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The occurrence of multiple copies of the c-erbB-2 in a percentage of colon lesions, however, suggests a possible role for this gene in some colon malignancies.
|
2571966 |
1989 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that 11p14 allelic loss plays a role in the evolution of human breast cancer, amplification of c-erbB-2 gene is associated with increasing stage of malignancy, and alteration of the c-myc gene in inflammatory breast carcinoma may contribute to the rapid progression of this human tumor subtype.
|
2573420 |
1989 |